Clinical Trials List
Protocol NumberUBP-A103-HER2
2018-03-05 - 2019-03-31
Phase I
Terminated1
-
Trial Applicant
-
Sponsor
-
Trial scale
Taiwan Single Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- 張平穎 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
24 participants
-
Global
24 participants
